Hilltop Leaf has been issued a high THC cannabis cultivation licence by Home Office Controlled Drug licensing.
Private Medicinal Cannabis cultivation and extraction business Hilltop Leaf has been issued the licence which will enable the company to undertake cultivation activities with certain schedules of Controlled Drugs: Schedule 1 Cultivation High THC Cannabis.
The licence has been issued in accordance with the Misuse of Drugs Act 1971 and its associated Misuse of Drugs Regulations 2001.
Hilltop Leaf CEO, co-founder and director, Hamish Clegg, said: “I would like to thank our incredible multidisciplinary team for the tireless work to create both the Quality Control Systems and the Operating Facilities and Systems to reach this fundamental milestone for our business.
“All of this has been achieved with the help of a much wider support group including our shareholders, contractors and supportive families who have backed us to get this far in our exciting project.
“The next phase of our project takes us to systems validation, research, future project planning and commercial discussions. We will be launching a Series A EIS capital raise to take us to the next level in the coming months.”
Neil Ewart, director, chairman and co-founder of Hilltop, added: “Hilltop has achieved another major milestone. Following our capital raise earlier in the year we have built a robust team to get us to this exciting junction where we move from project construction and planning stages to being a Life Sciences and Pharmaceutical business.
“We strive to be a science-led company and look forward to delivering on our early research phase to lay the key foundations to support our long term commercial ambitions.”
